News Releases

Date Title and Summary View
October 15, 2020
– KVD900 Phase 2 Trial Recruitment Complete; Data Expected Before End of 2020 – – KVD824 Achieves Targeted Exposure Levels for Prophylaxis; IND Submission Expected Q1 2021 – – Oral Factor XIIa Inhibitor Program Announced – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct....
Additional Formats
September 14, 2020
– KVD900 On-Demand Data Expected Q4 2020 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 14, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease...
Additional Formats
September 11, 2020
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 11, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
August 3, 2020
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 3, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
July 1, 2020
– KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020 – – Oral HAE Prophylactic Candidate KVD824 Phase 2 Clinical Trial Planned to Commence in 2H 2020 – – Operations Funded into 2022 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul....
Additional Formats
May 28, 2020
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
April 9, 2020
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 9, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
April 7, 2020
– Response to Coronavirus Impact on Ongoing Clinical Trials – – Cash Runway Extended into 2022 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 7, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and...
Additional Formats
March 10, 2020
– Oral Hereditary Angioedema Franchise Phase 2 Clinical Trials on Track – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule...
Additional Formats
February 19, 2020
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 19, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
Displaying 1 - 10 of 12